Recruiting PHASE1/PHASE2 INTERVENTIONAL 4-arm NCT05753462

Phase 1/2a for Safety, PK and PD of SQY51 in Paediatric and Adult Patients Duchenne Muscular Dystrophy (AVANCE1)

Phase 1/2a, Monocentric, Open Label Study to Evaluate the Safety, PK and PD of SQY51 in Paediatric and Adult Patients With a Genetically Confirmed Diagnosis of Duchenne Muscular Dystrophy

Sponsor: Biotrial

Conditions Duchenne Muscular Dystrophy

Interventions Phase 1, SQY51 Phase 2a, SQY51 (cohort 1) Phase 2a, SQY51 (cohort 2) Phase 2a, SQY51 (cohort 3)

Updated 5 times since 2023 Last updated: Mar 28, 2024 Started: Apr 26, 2023 Primary completion: Feb 28, 2025 Completion: Feb 28, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05753462, this PHASE1/PHASE2 trial focuses on Duchenne Muscular Dystrophy and remains actively recruiting participants. Sponsored by Biotrial, it has been updated 5 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
May 2024 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2
Jun 2023 — May 2024 [monthly]

Recruiting PHASE1_PHASE2
Apr 2023 — Jun 2023 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Biotrial
Sqy Therapeutics

Data source: Sqy Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Garches, France